

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. Securities may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission or an exemption from registration. Neither this announcement nor any content contained herein shall form the basis of any contract or commitment whatsoever. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer or the selling security holder and that will contain detailed information about the company and management, as well as financial statements. Any such offer or invitation will be made only in jurisdictions in which it may be legally and validly made.*



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司\***  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1548)**

**UPDATE ON THE DISCLOSEABLE TRANSACTION AND  
THE DECLARATION OF A DISTRIBUTION IN RELATION TO  
THE SPIN-OFF AND SEPARATE LISTING OF  
LEGEND BIOTECH CORPORATION ON THE NASDAQ GLOBAL MARKET**

The Spin-off of Legend Biotech and its listing on the Nasdaq Global Market took place on 5 June 2020 (New York time) at a final offer price under the Offering of US\$23.00 (equivalent to approximately HK\$178.25) per ADS.

The net proceeds received by Legend Biotech from the Offering and the Concurrent Private Placement are approximately US\$390.4 million (equivalent to approximately HK\$3.03 billion), or approximately US\$453.9 million (equivalent to approximately HK\$3.52 billion) if the Underwriters exercise their option to purchase additional ADSs in full, based on the ADS Offer Price, after deducting underwriting discounts and commissions and the estimated offering expenses payable by Legend Biotech.

The Board is pleased to announce that in giving due regard to the interests of the Shareholders as required under PN15, the Board has passed on 5 June 2020 a resolution to declare a special dividend of approximately HK\$114.9 million to the Shareholders by way of a distribution on the following basis:

- (i) A Qualifying Shareholder holding a whole multiple of a Qualifying Lot (i.e. 2,950 Shares) on the Record Date will be entitled to a Distribution of one ADS for every whole multiple of a Qualifying Lot held. Such Shareholder may elect to receive (a) the ADS(s) to which they are entitled, or, (b) in lieu of such ADS(s), a cash payment equal to the ADS Offer Price per ADS in Hong Kong dollars (rounded to the nearest); or (c) part of the Distribution by way of ADS(s) and part of the Distribution by way of cash payment, both to be calculated in accordance with the principles discussed above.

- (ii) Fractional ADSs will not be distributed. A Qualifying Shareholder who holds Shares in excess of a whole multiple of a Qualifying Lot will be entitled to a cash distribution of HK\$30.21 for every whole multiple of 500 Shares held in excess of the largest multiple of a Qualifying Lot held on the Record Date.
- (iii) Qualifying Shareholders who hold less than a Qualifying Lot and Non-Qualifying Shareholders will not be entitled to elect to receive ADSs, but will instead receive cash in lieu of the ADSs to which they would otherwise receive on the basis that for every 500 Shares held on the Record Date, such Shareholder will be entitled to a cash distribution of HK\$30.21.
- (iv) Any Shareholder who holds less than 500 Shares on the Record Date will not receive any cash distribution as entitlement to sums of less than HK\$30.21 will not be distributed and will be retained for the benefit of the Company.

On 5 June 2020 (New York time), concurrently with the completion of the Offering, the Company has agreed to purchase from Legend Biotech 1,043,478 ordinary shares at the ADS Offer Price as adjusted by the ADS-to-ordinary share ratio and on the same terms as the ADSs being offered to the public investors in the U.S.. The consideration payable by the Company for the Concurrent Private Placement amounts to approximately US\$12.00 million (equivalent to approximately HK\$93.00 million).

## **GENERAL**

**Qualifying Shareholders are reminded that whether or not it is to their advantage to elect to receive the Distribution in cash in lieu of the Distribution ADSs depends upon their own individual circumstances and preference, and the decision in this regard and all effects resulting therefrom are the responsibility of each individual Qualifying Shareholder.**

**This announcement is not, and does not form part of, an offer to sell or solicitation of an offer to purchase or subscribe for any securities of Legend Biotech in Hong Kong, the U.S. or any other jurisdiction, and neither this announcement, nor any part of it, shall form the basis of, or be relied on in connection with, any investment decision relating to securities of Legend Biotech. The ADSs referred to in this announcement may not be offered or sold unless registered under the Securities Act or an exemption from registration is available.**

References are made to the Company's announcements dated 10 March 2020, 16 March 2020, 14 May 2020, 26 May 2020, 29 May 2020, and 5 June 2020 and in respect of the Spin-off.

## **ASSURED ENTITLEMENT**

The Spin-off of Legend Biotech and its listing on the Nasdaq Global Market took place on 5 June 2020 (New York time) at a final offer price under the Offering of US\$23.00 (equivalent to approximately HK\$178.25) per ADS.

The net proceeds received by Legend Biotech from the Offering and the Concurrent Private Placement are approximately US\$390.4 million (equivalent to approximately HK\$3.03 billion), or approximately US\$453.9 million (equivalent to approximately HK\$3.52 billion) if the Underwriters exercise their option to purchase additional ADSs in full, based on the ADS Offer Price, after deducting underwriting discounts and commissions and the estimated offering expenses payable by Legend Biotech.

The Board is pleased to announce that in giving due regard to the interests of the Shareholders as required under PN15, the Board has passed on 5 June 2020 a resolution to declare a special dividend of approximately HK\$114.9 million to the Shareholders by way of a distribution on the following basis:

- (i) A Qualifying Shareholder holding a whole multiple of a Qualifying Lot on the Record Date will be entitled to a Distribution of one ADS for every whole multiple of a Qualifying Lot held. Such Shareholder may elect to receive (a) the ADS(s) to which they are entitled, or, (b) in lieu of such ADS(s), a cash payment equal to the ADS Offer Price per ADS in Hong Kong dollars (rounded to the nearest); or (c) part of the Distribution by way of ADS(s) and part of the Distribution by way of cash payment, both to be calculated in accordance with the principles discussed above.
- (ii) Fractional ADSs will not be distributed. A Qualifying Shareholder who holds Shares in excess of a whole multiple of a Qualifying Lot will be entitled to a cash distribution of HK\$30.21 for every whole multiple of 500 Shares held in excess of the largest multiple of a Qualifying Lot held on the Record Date.
- (iii) Qualifying Shareholders who hold less than a Qualifying Lot and Non-Qualifying Shareholders will not be entitled to elect to receive the ADSs, but will instead receive cash in lieu of the ADSs to which they would otherwise receive on the basis that for every 500 Shares held on the Record Date, such Shareholder will be entitled to a cash distribution of HK\$30.21.
- (iv) Any Shareholder who holds less than 500 Shares on the Record Date will not receive any cash distribution as entitlement to sums of less than HK\$30.21 will not be distributed and will be retained for the benefit of the Company.

### **Qualifying Shareholders**

Qualifying Shareholders are the Shareholders whose names appear on the register of members of the Company on the Record Date, other than the Shareholders who are, or who are acting for the account or benefit of, Non-Qualifying Shareholders.

## **Non-Qualifying Shareholders**

Non-Qualifying Shareholders are the Shareholders (including beneficial owners) who are:

- (i) on the Record Date, resident or located in places outside Hong Kong in respect of which the Directors considers the exclusion from receiving the ADSs under the Distribution to be necessary or expedient on account of either the legal restrictions under the laws of the relevant place or the requirements of a regulatory body or stock exchange in that place, in accordance with Rule 13.36(2) of the Listing Rules; or
- (ii) otherwise unable to make the certifications required in the Form of Election in order to be entitled to receive the Distribution ADSs.

The Company reserves the right to adopt the same approach in respect of any other jurisdiction(s) where the applicable laws of the relevant jurisdiction make it necessary or expedient to do so.

## **Overseas Shareholders and Stock Connect Investors**

Under Rule 13.36(2) of the Listing Rules, where a listed issuer proposes to distribute securities to its shareholders, it may exclude relevant overseas shareholders in circumstances where the directors consider the exclusion to be necessary or expedient on account either of the legal restrictions under the laws of the relevant place or the requirements of the relevant regulatory body or stock exchange in that place.

Based on the register of members of the Company as at 30 May 2020, all the Shareholders had registered addresses in Hong Kong, except for one Shareholder in the U.S. who is an “accredited investor” as defined under Rule 501 of Regulation D of the Securities Act and therefore, it is a Qualifying Shareholder.

Notwithstanding the above, the Board reserves the right to exclude any other registered Shareholder whose address as shown on the register of members of the Company on the Record Date is located in any overseas jurisdiction from the Distribution, if the Board believes that such distribution may be administratively prohibitive or inexpedient or violate any applicable legal and/or regulatory requirements in the relevant jurisdiction. If and when necessary, the Company will separately notify any such Shareholder of the arrangement regarding the Distribution.

As at the date of this announcement, pursuant to Article 24 of the Implementation Rules for Registration, Depository and Clearing Services under the Mainland-Hong Kong Stock Markets Connect Programme (《內地與香港股票市場交易互聯互通機制登記、存管、結算業務實施細則》), if the Stock Connect Investors receive any securities not listed on the Stock Exchange, they will not be allowed to buy or sell such securities through the Stock Connect. Considering the practical difficulty of the Stock Connect Investors in realizing the benefit of the Distribution ADSs, Stock Connect Investors will not be able to elect to receive the Distribution ADSs and so will only receive the cash distribution instead, the amount of which is subject to finalized distribution arrangement determined by the Company. This arrangement is in accordance with Question No. 4 of the Frequently Asked Questions Series 29 released by the Stock Exchange on 17 November 2014 and last updated on 13 July 2018.

A Shareholder with an address outside Hong Kong should consult his own professional advisers as to whether or not he is permitted to receive the Distribution ADSs pursuant to the Distribution or if any governmental or other consent is required or other formalities are required to be observed and whether there are any other restrictions in relation to the future sale of any Distribution ADSs or ADSs. An overseas Qualifying Shareholder residing in a jurisdiction where it would be illegal for him/her/it to elect for or to receive the Distribution ADSs under the Distribution will be deemed to have received the Form of Election for information purpose only.

### **Circular and Form of Election**

A Qualifying Shareholder holding a Qualifying Lot on the Record Date will be sent a Circular and a Form of Election. The Form of Election will set out the number of the Distribution ADSs to which the relevant Qualifying Shareholder is entitled.

Any Non-Qualifying Shareholder who receives a Form of Election will be deemed to have received the Form of Election for information purpose only.

### **Qualifying Shareholders holding a Qualifying Lot who wish to receive cash**

Any Qualifying Shareholder holding a Qualifying Lot on the Record Date who wishes to receive cash in lieu of all the Distribution ADSs to which he/she/it would otherwise be entitled do not need to take any action in respect of the Form of Election.

### **Qualifying Shareholders holding less than a Qualifying Lot**

The Form of Election will only be sent to, and only needs to be completed by, a Qualifying Shareholder holding a Qualifying Lot on the Record Date. Qualifying Shareholders holding less than a Qualifying Lot on the Record Date and Non-Qualifying Shareholders will receive cash on the basis specified in this announcement.

### **Qualifying Shareholders holding a Qualifying Lot who wish to receive the Distribution ADSs**

Any Qualifying Shareholder holding a Qualifying Lot on the Record Date who wishes to receive the Distribution ADSs must return a validly completed Form of Election. In addition to making certain other certifications and agreements in the Form of Election, a Qualifying Shareholder who wishes to receive the Distribution ADSs must certify in the Form of Election that if he/she/it is located in the U.S., such shareholder is an “accredited investor” as defined under Rule 501 of Regulation D of the Securities Act. For a Qualifying Shareholder who is holding Shares as a nominee, trustee, depository or any other authorised custodian, such Shareholder must also certify that if he/she/it is receiving the Distribution ADSs for the account or benefit of, a beneficial owner located in the U.S, such beneficial owner is an “accredited investor” as defined under Rule 501 of Regulation D of the Securities Act. A Shareholder who returns a Form of Election but fails to provide the required certifications and agreements in the Form of Election will be deemed a Non-Qualifying Shareholder and will receive cash on the basis specified in this announcement.

Any Qualifying Shareholder holding a Qualifying Lot should note that he/she/it is able to receive the Distribution ADSs only if he/she/it specifies in the Form of Election information as to the details of his/her/its DTC participant account and/or the details of his/her/its broker or dealer who is a direct or indirect DTC participant, the details of that broker's/dealer's DTC participant name, account, and contact telephone number to which the Distribution ADSs can be credited and such broker or dealer accepts such Distribution ADSs for crediting. Information specified on a Form of Election must be complete and valid, failing which, the Qualifying Shareholder listed on that Form of Election will be deemed to have elected to receive cash in lieu of the Distribution ADSs to which he/she/it is entitled. Qualifying Shareholders who have elected to receive the Distribution ADSs must instruct and coordinate with their respective brokers/dealers on their elections and the settlement of their respective Distribution ADSs.

To be valid, the Form of Election, together with any power of attorney (where applicable) and/or other authority under which it is signed (where applicable) or notarially certified copy thereof, must be returned to the office of the Share Registrar no later than 4:30 p.m. on Tuesday, 14 July 2020. No acknowledgment of receipt of the Form of Election will be issued. A Qualifying Shareholder is deemed to have elected to receive cash in lieu of the Distribution ADSs to which he/she/it is entitled if such Qualifying Shareholder fails to return a valid Form of Election.

Any Form of Election will be treated as invalid if:

- it is incomplete; or
- it contains illegible writing; or
- the Shareholder is unable to provide the correct details of his/her/its broker or dealer (including details of the DTC participant, account and other information listed on the Form of Election) and the account to which the Distribution ADSs are to be credited; or
- the broker or dealer is not a direct or indirect DTC participant or refuses to accept the Distribution ADSs, such that the Distribution ADSs could not be credited for the account specified in the Form of Election.

The latest time for submission of the Forms of Election will not be valid if there is a tropical cyclone warning signal no. 8 or above, or a "black" rainstorm warning:

- (a) in force in Hong Kong at any local time before 12:00 noon and no longer in force after 12:00 noon on 14 July 2020. In which case, the deadline for the submission of the Forms of Election will be 4:30 p.m. on the same Hong Kong business day; or
- (b) in force in Hong Kong at any local time between 12:00 noon and 4:30 p.m. on 14 July 2020. In which case, the deadline for the submission of the Forms of Election will be rescheduled to 4:30 p.m. on the next Hong Kong business day which does not have either of those warnings in force at any time between 9:00 a.m. and 4:30 p.m.

### **Despatch of cheques**

Cheques for all cash payments are expected to be despatched by ordinary post to the address specified in the register of members, at the risk of the relevant Shareholder, on Thursday, 23 July 2020.



## **Qualifying Shareholders holding Shares as trustees and beneficial owners**

Any Qualifying Shareholder who holds Shares as a nominee, trustee or registered holder in any other capacity will not be treated differently from any other registered holders. Any beneficial owner of Shares which is registered in the name of a nominee, trustee or registered holder in any other capacity should make arrangements with such nominee, trustee or registered holder in relation to the Distribution. Any such person may consider whether he/she/it wishes to arrange for the registration of the relevant Shares in the name of the beneficial owner prior to ex-entitlement of the Distribution, however, any costs, taxes or duties associated therewith or arising therefrom will be borne solely by such Shareholder.

## **Restrictions on sales of the Distribution ADSs for 40 days after delivery**

In accordance with the requirements of US securities laws, Qualifying Shareholders receiving the Distribution ADSs will not be permitted to sell, transfer or otherwise dispose of their Distribution ADSs within the U.S. or to, or for the account or benefit of, US Persons (as defined in Regulation S under the Securities Act) during the period of 40 days commencing on the date of the last issuance of the Distribution ADSs to Qualifying Shareholders. After the expiry of that 40-day period, the Distribution ADSs held by Qualifying Shareholders who are not (i) US Persons; (ii) persons located in the U.S.; or (iii) Legend Biotech Affiliates, will be tradable on the Nasdaq Global Market on the same basis as the ADSs issued under the Offering.

Distribution ADSs held by Qualifying Shareholders who are (i) US Persons; (ii) persons located in the U.S.; or (iii) Legend Biotech Affiliates, will be subject to additional restrictions on disposal.

## **Holding of the Distribution ADSs through the DTC**

The Distribution ADSs are to be held electronically in book entry form through the facilities of the DTC directly in the name of a Qualifying Shareholder who has elected to receive the Distribution ADSs (only if such Qualifying Shareholder is a participant in the DTC) or indirectly through the Qualifying Shareholder's account at a broker/dealer or other financial institution which is a direct or indirect participant in the DTC.

After the 40-day period as set out above, at the direction of Legend Biotech and the Company, the DTC will credit the account of (i) a Qualifying Shareholder (if such Qualifying Shareholder is a participant in the DTC) or (ii) the broker/dealer or other financial institution which is a direct or indirect participant in the DTC designated by such Qualifying Shareholder, with the number of the Distribution ADSs to which such Qualifying Shareholder is entitled and has elected to receive.

Any Qualifying Shareholder holding a Qualifying Lot should note that he/she/it is able to receive the Distribution ADSs only if he/she/it can provide the details of his/her/its DTC participant account or the details of his/her/its broker/dealer or other financial institution who is a direct or indirect DTC participant, the details of that broker's/dealer's or other financial institution's DTC participant name, account, and contact telephone number to which the Distribution ADSs can be credited and such broker/dealer or other financial institution accepts such Distribution ADSs for crediting.

**Qualifying Shareholders who have elected to receive the Distribution ADSs must instruct and coordinate with their respective brokers/dealers or other financial institutions on their elections and the settlement of their respective Distribution ADSs.**

## **Distribution ADSs**

The Distribution ADSs are listed on the Nasdaq Global Market. The ticker symbol of Legend Biotech on the Nasdaq Global Market is “LEGN”.

## **EXPECTED TIMETABLE FOR THE DISTRIBUTION**

The expected timetable for the Distribution is as follows:

*All time and dates referred to below are Hong Kong time unless otherwise indicated.*

Dealings in the ADS on the Nasdaq Global Market commenced at <sup>(note)</sup>	9:30 p.m. on Friday, 5 June 2020
Latest day for dealing in Shares on a cum-entitlement basis	Wednesday, 17 June 2020
First day of dealing in Shares on an ex-entitlement basis	Thursday, 18 June 2020
<b>Latest time for lodging transfers of Shares cum-entitlement to the Distribution</b>	4:30 p.m. on Friday, 19 June 2020
Register of members of the Company closes from	Monday, 22 June 2020 to Tuesday, 23 June 2020 (both days inclusive)
Record Date for determining the entitlement to the Distribution	Tuesday, 23 June 2020
Register of members re-opens	Wednesday, 24 June 2020
Despatch of Circular and the Form of Election	Monday, 29 June 2020
<b>Latest time for lodging the Form of Election</b>	4:30 p.m. on Tuesday, 14 July 2020
Distribution of the Distribution ADSs	Thursday, 23 July 2020
Despatch of cheques for cash	Thursday, 23 July 2020

### *Note:*

Dealings in the ADSs on the Nasdaq Global Market commenced at 9:30 a.m. on 5 June 2020 (New York time).

Please note that the timetable is subject to change. If there are changes to the above timetable, the Company will publish an announcement to inform the Shareholders.



## **REASONS FOR AND BENEFITS OF THE CONCURRENT PRIVATE PLACEMENT**

The Company's shareholding in Legend Biotech is expected to be reduced due to (i) dilution caused by the issue and sale of Legend Biotech Shares in the Offering and (ii) the Distribution to be conducted by the Company to its Qualifying Shareholders as required by PN15.

The Directors consider the Concurrent Private Placement is beneficial to the Company for the following reasons:

- the Company will be able to replenish its shareholding in Legend Biotech through the purchase of additional ordinary shares; and
- the Concurrent Private Placement will provide financial supports to the business development and promote the fast growth of Legend Biotech, which in turn will enhance the shareholder value of the Company.

The Board (including the independent non-executive Directors) are of the view that the Concurrent Private Placement is on normal commercial terms which are fair and reasonable and in the interests of the Company and the shareholders of the Company as a whole.

## **FIXING OF RECORD DATE AND CLOSURE OF REGISTER OF MEMBERS**

Based on the expected timetable of the Distribution, the register of members of the Company will be closed from Monday, 22 June 2020 to Tuesday, 23 June 2020 (both days inclusive) for the purpose of determining the entitlement to the Distribution, and will be re-opened on Wednesday, 24 June 2020. No transfer of the Shares may be registered during such book close period.

In order to qualify for the Distribution, all transfer forms accompanied by the relevant share certificates must be lodged with the Share Registrar not later than 4:30 p.m. on Friday, 19 June 2020.

## **GENERAL**

**Qualifying Shareholders are reminded that whether or not it is to their advantage to elect to receive the Distribution in cash in lieu of the Distribution ADSs depends upon their own individual circumstances and preference, and the decision in this regard and all effects resulting therefrom are the responsibility of each individual Qualifying Shareholder.**

**This announcement is not, and does not form part of, an offer to sell or solicitation of an offer to purchase or subscribe for any securities of Legend Biotech in Hong Kong, the U.S. or any other jurisdiction, and neither this announcement, nor any part of it, shall form the basis of, or be relied on in connection with, any investment decision relating to securities of Legend Biotech. The ADSs referred to in this announcement may not be offered or sold unless registered under the Securities Act or an exemption from registration is available.**

## DEFINITION

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

“ADS(s)”	American depositary shares to be issued pursuant to a deposit agreement between Legend Biotech and JPMorgan Chase Bank, N.A., each representing 2 shares in Legend Biotech, which are expected to be listed on the Nasdaq Global Market;
“ADS Offer Price”	US\$23.00 (equivalent to approximately HK\$178.25), the initial public offer price of an ADS under the Offering;
“Board”	the board of Directors;
“Circular”	a shareholders’ circular containing the detailed terms and conditions of the Distribution and the detailed procedures and certification requirements for accepting the Distribution, which will accompany the Form of Election;
“Company”	Genscript Biotech Corporation 金斯瑞生物科技股份有限公司* (Stock Code: 1548), a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the main board of the Stock Exchange;
“control(s)”	the power to direct the management and policies of the person in question, whether through the ownership of voting securities, by contract, or otherwise and “controlled” shall be construed accordingly;
“Director(s)”	the director(s) of the Company;
“Distribution”	the proposed special dividend of the Company, to be satisfied by the distribution of the Distribution ADSs and/or the payment of cash to Qualifying Shareholders on and subject to the terms and conditions set out in this announcement and to be set out in the Circular;
“Distribution ADSs”	the ADSs to be distributed to Qualifying Shareholders pursuant to the Distribution;
“DTC”	the Depositary Trust Company;
“Form(s) of Election”	the form of election to be completed by Qualifying Shareholders who hold a Qualifying Lot pursuant to which such Qualifying Shareholder may elect to receive the Distribution ADSs or cash in lieu of all the Distribution ADSs to which they are entitled;
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong;

“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China;
“Legend Biotech”	Legend Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands with limited liability;
“Legend Biotech Shares”	ordinary shares of par value US\$0.0001 each in the capital of Legend Biotech;
“Legend Biotech Affiliate(s)”	(i) any person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, Legend Biotech; or (ii) an executive officer, a director, or a large shareholder that is in a relationship of control with Legend Biotech;
“Listing Rules”	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange;
“Non-Qualifying Shareholder(s)”	(i) the Shareholders (including beneficial owners) on the Record Date who are resident or located in places outside Hong Kong in respect of which the Directors considers the exclusion from receiving the ADSs under the Distribution to be necessary or expedient on account of either the legal restrictions under the laws of the relevant place or the requirements of a relevant regulatory body or stock exchange in that place; or (ii) the Shareholders (including beneficial owners) who are otherwise unable to make the certifications required in the Form of Election in order to be entitled to receive the Distribution ADSs;
“Offering”	the initial public offering of the ADSs in connection with the Spin-off;
“PN15”	Practice Note 15 of the Listing Rules;
“PRC”	the People’s Republic of China;
“Qualifying Lot”	2,950 Shares;
“Qualifying Shareholder(s)”	the Shareholders whose names appear on the register of members of the Company on the Record Date, other than the Shareholders who are, or who are acting for the account or benefit of, Non-Qualifying Shareholders;
“Record Date”	23 June 2020, the date by reference to which entitlements to the Distribution are determined;
“Securities Act”	the United States Securities Act of 1933, as amended;
“Share Registrar”	the branch share registrar of the Company, namely Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong;

“Share(s)”	ordinary share(s) of US\$0.001 each in the share capital of the Company (or of such other nominal amount as shall result from a sub-division, consolidation, reclassification or reconstruction of the share capital of the Company from time to time);
“Shareholder(s)”	holder(s) of the Share(s);
“Spin-off”	the spin-off listing of the Company’s majority-owned cell therapy business operated by Legend Biotech involving the Offering and the separate listing of the ADSs on the Nasdaq Global Market;
“Stock Connect”	Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect;
“Stock Connect Investor(s)”	the PRC southbound trading investor(s) holding the Company’s securities through the Stock Connect;
“Stock Exchange”	The Stock Exchange of Hong Kong Limited;
“U.S.”	The United States;
“Underwriters”	the underwriters to Offering;
“US\$”	United States Dollar, the lawful currency of the United States of America; and
“US Person(s)”	as defined in Rule 902 under the Securities Act.

*For the purpose of this announcement, unless otherwise indicated, the exchange rate of US\$1.00 = HK\$7.75 has been used, where applicable, for the purpose of illustration only and does not constitute a representation that any amount has been, could have been or may be exchanged at such rate or any other rate or at all on the date or dates in question or any other date.*

**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Nanjing, People’s Republic of China  
7 June 2020

*As at the date of this announcement, the executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye and Mr. MENG Jiange; the non-executive Directors are Dr. WANG Luquan, Mr. PAN Yuexin and Ms. WANG Jiafen; and the independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian and Mr. PAN Jiu.*

\* *For identification purposes only*